181 related articles for article (PubMed ID: 22137075)
1. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study.
Woo JS; Kim W; Lee SR; Jung KH; Kim WS; Lew JH; Lee TW; Lim CK
Am Heart J; 2011 Dec; 162(6):1018-25. PubMed ID: 22137075
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
[TBL] [Abstract][Full Text] [Related]
3. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.
Gremmel T; Müller M; Steiner S; Seidinger D; Koppensteiner R; Kopp CW; Panzer S
Nephrol Dial Transplant; 2013 Aug; 28(8):2116-22. PubMed ID: 23729489
[TBL] [Abstract][Full Text] [Related]
5. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
6. Regarding the "Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study".
Alexopoulos D
Am Heart J; 2012 May; 163(5):e31; author reply e33. PubMed ID: 22607871
[No Abstract] [Full Text] [Related]
7. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
8. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
[TBL] [Abstract][Full Text] [Related]
9. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK
Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567
[TBL] [Abstract][Full Text] [Related]
10. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Jeong KH; Cho JH; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W
Am J Kidney Dis; 2015 Jun; 65(6):916-24. PubMed ID: 25622774
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
[TBL] [Abstract][Full Text] [Related]
13. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
[TBL] [Abstract][Full Text] [Related]
14. Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
Leng WX; Ren JW; Cao J; Cong YL; Cui H; Hu GL; Hu QQ; Niu H; Fan L
Thromb Res; 2013 Mar; 131(3):218-24. PubMed ID: 23340097
[TBL] [Abstract][Full Text] [Related]
15. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.
Kim JY; Lee K; Shin M; Ahn M; Choe H; Yoo BS; Yoon J; Choe KH; Lee SH
Circ J; 2007 Dec; 71(12):1867-72. PubMed ID: 18037738
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
17. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
Alexopoulos D; Xanthopoulou I; Plakomyti TE; Theodoropoulos KC; Mavronasiou E; Damelou A; Hahalis G; Davlouros P
Am Heart J; 2013 Jan; 165(1):73-9. PubMed ID: 23237136
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P
J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
